Actively Recruiting
Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection
Led by Chinese University of Hong Kong · Updated on 2025-05-20
510
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective clinical study recruiting 510 men at risk of PCa to undergo urine, blood, AI-assisted ultrasound and AI-assisted MRI investigations to stratify risk of clinically significant PCa (csPCa). (sample size calculation in section 5)
CONDITIONS
Official Title
Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men 18 years of age or older
- Clinical suspicion of prostate cancer
- Serum Prostate-specific antigen (PSA) between 4 and 20 ng/mL
- Digital rectal examination showing organ confined cancer (cT2 or less)
- Able to provide written informed consent
You will not qualify if you...
- Prior prostate biopsy
- Past or current history of prostate cancer
- Unable to undergo plain MRI scan (e.g., pacemaker, claustrophobia)
- Unable to have transperineal prostate biopsy due to active urinary infection, failed TRUS probe insertion or lithotomy position, uncorrectable bleeding disorders, or unstoppable antiplatelet/anticoagulant therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital, Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
P
Peter Ka-Fung CHIU, FRCS, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here